Growth Factors, Cytokines, Cell Cycle Molecules

Phosphorylation of Ephrin-B1 Regulates Dissemination of Gastric Scirrhous Carcinoma

Masamitsu Tanaka,* Reiko Kamata,*
Misato Takigahira,[†] Kazuyoshi Yanagihara,[†] and
Ryuichi Sakai*

From the Growth Factor Division,* Central Animal Laboratory,[†]
National Cancer Center Research Institute, Tokyo, Japan

Interaction of the Eph family of receptor protein tyrosine kinase and its ligand ephrin family induces bidirectional signaling via cell-cell contacts. High expression of B-type ephrin is frequently found in various cancer cells, and their expression levels are associated with high invasion of tumors and poor prognosis. However, whether ephrin-B1 actually promotes invasion of cancer cells *in vivo* has not been shown. We investigated the involvement of ephrin-B1 in regulating the invasiveness of scirrhous gastric cancer, which is a diffusely infiltrative carcinoma with high invasion potential. Reduction of ephrin-B1 expression by short interfering RNA or overexpression of phosphorylation-defective mutant suppressed migration and invasion of scirrhous gastric cancer cells *in vitro* without affecting tumor cell proliferation and apoptosis. Blocking of tyrosine phosphorylation of ephrin-B1 attenuates not only dissemination of cancer cells injected intraperitoneally but also local invasion and dissemination of orthotopically implanted cancer cells in the gastric wall of nude mice. Furthermore, blocking of ephrin-B1 phosphorylation attenuated the activation of Rac1 GTPase in these invasive gastric cancer cells. Our results suggest that tyrosine phosphorylation of ephrin-B1 promotes invasion of cancer cells *in vivo* and is a potential therapeutic target in some types of gastrointestinal cancers. (Am J Pathol 2007, 171:68–78; DOI: 10.2353/ajpath.2007.070033)

Members of the Eph receptor family can be classified into two groups based on their sequence similarity and their preferential binding to the subset of ligands tethered to the cell surface either by a glycosylphosphatidyl inositol-anchor (ephrin-A) or a transmembrane domain (ephrin-B).^{1–3} Interaction of the EphB family of receptor protein tyrosine kinases and its ligand ephrin-B family induces bidirectional signaling via cell-cell contacts.

The biological functions of Ephs and ephrins in epithelial cells and tumors have recently been highlighted.^{4–9} For example, EphB receptors and ephrin-B ligands are expressed in normal intestinal epithelium, which contributes for the restriction of cell migration and positioning along the crypt-villus axis.⁴ Overexpression of B-type ephrin in cancer cells correlates with poor prognosis characterized by high invasion and high vascularity of the tumors.^{10–15} Expression of ephrin-B2 has been reported in invasive tumor cells and is often highly expressed in the peripheral region of the tumors especially at the front of the invasion.¹¹ Ephrin-B1 is frequently overexpressed in gastrointestinal tumors, especially in poorly differentiated invasive tumor cells.¹⁵ Although an accumulating number of reports have suggested that expression of B-type ephrin is closely associated with tumor cell invasion, whether ephrin-B modifies tumor invasion *in vivo* has not been well established.

Ephrin-Bs are tyrosine phosphorylated via Src family kinases in response to the interaction with EphB receptors, which serves as a docking site for Src homology 2 domain of adaptor protein Grb4, and transduce intracellular signaling.^{16,17} We have also demonstrated that ephrin-B1 is phosphorylated independently of Eph receptors through association with an intercellular adhesion molecule, which leads to attenuation of cell-cell adhesion.⁷ In our recent observations, signaling mediated by ephrin-B1 promoted the process of intracellular transport and secretion of matrix metalloproteinase (M. Tanaka, K. Sasaki, R. Kamata, and R. Sakai, unpublished data), which led us to examine in this study whether disruption of ephrin-B1-mediated signaling, especially through the tyrosine phosphorylation of ephrin-B1, could suppress tumor cell invasion.

Supported by the Program for the Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research of Japan.

Accepted for publication April 10, 2007.

Supplemental material for this article can be found on <http://ajp.amjpathol.org>.

Address reprint requests to Ryuichi Sakai, Growth Factor Division, Central Animal Laboratory, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045. E-mail: rsakai@gan2.res.ncc.go.jp.

Scirrhou gastric carcinoma diffusely infiltrates a broad region of the stomach and frequently associates with metastasis to lymph nodes and peritoneal dissemination and, therefore, has the worst prognosis among various types of gastric cancers. We previously established two cell lines of human gastric scirrhou carcinoma possessing high infiltrative potential by repeating cycles of orthotopic transplantation in nude mice and collecting cancer cells from the ascitic fluid formed as a result of cancerous peritonitis.^{18,19} In this study, we show that reduction of ephrin-B1 expression or blocking of tyrosine phosphorylation of ephrin-B1 inhibits tumor invasion of these highly invasive gastric cancer cells. Our results suggest that ephrin-B1 represents a rational therapeutic target and that suppression of its phosphorylation is a strategy for modulating the invasion of some types of cancers.

Materials and Methods

Plasmids, Antibodies, and Reagents

Plasmids encoding full-length cDNAs of human ephrin-B1 and ephrin-B1 with mutations of four tyrosine residues in the cytoplasmic domain (Y313, 317, 324, and 329) ephrin-B1 4YF have already been described.⁷ To generate the recombinant retrovirus, cDNAs were subcloned into the vector pDON-AI (Takara, Kyoto, Japan). The rabbit polyclonal antibodies for ephrin-B1 (C18) and α -tubulin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Polyclonal antibody against tyrosine-phosphorylated ephrin-B1 (ephrin-B1 pY317, amino acids 314 to 321, which is identical to corresponding region of ephrin-B2, 301 to 308, and ephrin-B3, 308 to 315) was raised in rabbits and affinity-purified as described previously.⁷ The monoclonal antibodies for phosphotyrosine (4G10) and Rac1 were from Upstate Biotechnology (Lake Placid, NY). The polyclonal antibodies for EphB2 and EphB4 were from R&D Systems (Minneapolis, MN). Fibronectin (bovine), collagen type I, and Matrigel basement membrane matrices were purchased from Sigma (St. Louis, MO), Nitta Gelatin, Inc. (Osaka, Japan), and BD Biosciences (San Jose, CA), respectively.

Cell Culture and Transfection

Gastric carcinoma cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. Mouse fibroblast L cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. L cells stably expressing EphB2 (L EphB2) were established through transfection of a plasmid encoding human ephrin-B1 in parent L cells, which do not express cognate receptors for ephrin-B1 as previously described,⁷ and selection in medium containing hygromycin B at a concentration of 400 μ g/ml. Recombinant retroviral plasmid pDON-AI was cotransfected with pCL-10A1 retrovirus packaging vector (Imgenex, San Diego, CA) into 293gp cells to allow the production of retroviral particles. Gastric cancer cells stably expressing ephrin-B1 4YF were established by infecting cancer cells with retroviruses and

selected in the medium containing G418 at a concentration of 500 μ g/ml for 3 weeks. The mixture of selected cells was used for the experiments.

In Vitro Short Interfering RNA (siRNA) Treatment

Two sets of Stealth siRNAs of ephrin-B1 were synthesized as follows (Invitrogen, Carlsbad, CA): ephrin-B1 sense 1, 5'-UAAGGGAAUGAUGAUGUCGCGUGG-3'; ephrin-B1 antisense 1, 5'-GCCCAGCGACAUCAUCAUCCCUUA-3'; ephrin-B1 sense 2, UAGUCCGUAAGGGAAUGAUGAUGUC-3'; and ephrin-B1 antisense 2, GACAUCAUCAUCCCUUACGGACUA-3'. The control siRNA (scramble II duplex, 5'-GCGCGCUUUGUAGGAUUCGdTdT-3') was purchased from Dharmacon (Lafayette, CO). siRNAs were incorporated into cells using Lipofectamine2000 according to the manufacturer's instructions (Invitrogen). Assays were performed 72 hours after treatment.

Immunoprecipitation

Cell lysates were prepared with protease inhibitors in PLC buffer [50 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5, 150 mmol/L NaCl, 1.5 mmol/L MgCl₂, 1 mmol/L ethylene glycol bis(β -aminoethyl ether)-N,N,N',N'-tetraacetic acid, 10% glycerol, 100 mmol/L NaF, 1 mmol/L Na₃VO₄, and 1% Triton X-100]. To precipitate the proteins, 1 μ g of affinity-purified polyclonal antibody was incubated with 500 μ g of cell lysate for 2 hours at 4°C and then precipitated with protein G agarose for 1 hour at 4°C. Immunoprecipitates were extensively washed with PLC buffer, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotted.

Affinity Precipitation

Affinity precipitation with GST-PBD (p21-binding domain of p21-activated kinase 1) was performed as described previously.²⁰ In brief, cells were lysed in the lysis buffer [50 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5, 150 mmol/L NaCl, 10 mmol/L MgCl₂, 1 mmol/L ethylene glycol bis(β -aminoethyl ether)-N,N,N',N'-tetraacetic acid, 10% glycerol, 100 mmol/L NaF, 1 mmol/L Na₃VO₄, and 1% Triton X-100] and incubated with GST-PBD on Sepharose for 1 hour at 4°C. Precipitants were washed three times in the same buffer, and endogenous Rac1 was detected by immunoblotting with anti-Rac1 antibody.

5-Bromo-2'-Deoxyuridine Incorporation

Cell proliferation was assessed by measurement of 5-bromo-2'-deoxyuridine (BrdU) incorporation into the DNA with Cell Proliferation enzyme-linked immunosorbent assay, BrdU (colorimetric) kit (Roche, Basel, Switzerland). In brief, gastric cancer cells were plated onto 96-well plates (1 $\times$ 10⁴ cells/well) 48 hours after treatment of siRNAs and further incubated for 24 hours before the addition of BrdU. Cells were reincubated for 6 hours,

and incorporated BrdU was detected with peroxidase-labeled anti-BrdU antibody and developed with tetramethyl-benzidine as a chromogenic substrate according to the manufacturer's instructions (Roche). The absorbance of the samples was measured at the wavelength of 450 nm using a microplate reader (model 550; Bio-Rad, Hercules, CA).

Apoptosis Assays

Gastric cancer cells were plated in triplicate onto 96-well plates (1×10^4 cells) 48 hours after treatment of siRNAs and incubated for 24 hours. Cells were lysed to detect apoptosis by measurement of nucleosomes in the cytoplasm of apoptotic cells using a Cell Death enzyme-linked immunosorbent assay kit according to the manufacturer's instructions (Roche Molecular Biochemicals). In brief, nucleosomes in cell lysates were detected with peroxidase-labeled anti-DNA antibody and developed with 2,2'-azino-di[3-ethylbenzthiazolin-sulfonate] as a chromogenic substrate. The absorbance of the samples was measured at the wavelength of 405 nm using a microplate reader (model 550; Bio-Rad).

Cell Attachment Assay

Cancer cells were detached by phosphate-buffered saline(-) [PBS⁽⁻⁾] containing ethylenediamine tetraacetic acid (2 mmol/L) and replated on the chamber slides coated with either collagen type I (100 μ g/ml; Nitta Gelatin, Inc.), fibronectin (50 μ g/ml; Sigma), or Matrigel (85 μ g/ml; Asahi Techno Glass Co., Tokyo, Japan). After incubation for 30 minutes, unattached cells were removed by washing the slides in PBS⁽⁻⁾ several times, and the remaining cells were stained with Giemsa's solution. The number of attached cells on each substrate was counted.

Cell Staining

Cells were fixed for 5 minutes at room temperature with 4% paraformaldehyde in PBS and permeabilized for 10 minutes with 0.2% Triton X-100. The cells were preincubated in 2% bovine serum albumin for 0.5 hour and incubated with Alexa546-conjugated phalloidin (Molecular Probes, Eugene, OR) for 1 hour at room temperature. Photos were taken with a Radiance 2100 confocal microscope (Bio-Rad).

Overlay Tumor Invasion Assay

Invasion of tumor cells into the monolayer of stromal cells was monitored basically as described previously.²⁰ Gastric cancer cells treated with ephrin-B1 siRNA or control siRNA were labeled with 2 mmol/L lipophilic tracer DiO (Molecular Probes) and then detached with Hanks' balanced salt solution⁻ containing 2 mmol/L ethylenediamine tetraacetic acid and seeded on the confluent monolayer of parent L cells or L EphB2 cells. After being

cultured in the medium with 10% fetal bovine serum for 15 hours, the cells were fixed with 4% paraformaldehyde in PBS, and the number of invasion foci of cancer cells was counted using fluorescence microscopy.

In Vivo Tumor Cell Invasion Assay

The animal experimental protocols were approved by the Committee for Ethics of Animal Experimentation, and the experiments were conducted in accordance with the guidelines for Animal Experiments in the National Cancer Center. Peritoneal dissemination of tumors was examined by intraperitoneal injection of 5×10^6 gastric cancer cells suspended in 0.3 ml of RPMI 1640 medium into 6-week-old BALB/c nude mice (CLEA Japan, Inc., Tokyo, Japan). The mice were sacrificed 2 weeks after injection, and peritoneal dissemination was evaluated. Orthotopic implantation of gastric cancer cells into BALB/c nude mice has been described previously.^{18,19} In brief, 1×10^6 cells were inoculated into the middle wall of the greater curvature of the glandular stomach by using a 30-gauge needle. The mice were sacrificed at different time points after the orthotopic transplantation of the cancer cells and subjected to macroscopic and histopathological examination of the tumors.

Results

Reduction of Ephrin-B1 Expression Attenuates Tumor Invasion of Gastric Cancer Cells

To examine the involvement of ephrin-B1 for invasion of tumors, we analyzed cell lines of scirrhous gastric carcinoma, which is characterized as reduced cell-cell adhesion with high invasion potential. HSC-44PE and HSC-58 were originally established from the patients of scirrhous gastric carcinoma, and highly invasive sublines were further selected from these parent cells (44As3 from HSC-44PE; 58As1 and 58As9 from HSC-58^{18,19}). Both expression and phosphorylation levels of ephrin-B1 were higher in cells of invasive sublines than in corresponding parent cell lines, whereas the expression level of control α -tubulin was not altered in these cell lines (Figure 1a). In addition, EphB2 was expressed in all of these cell lines, and HSC-44PE and 44As3 cells also expressed EphB4, showing the existence of cognate receptors (Figure 1a).

We next examined whether reduction of ephrin-B1 expression affects cell motility and proliferation of these gastric cancer cells. The treatment of cells with two independent siRNA of ephrin-B1 effectively reduced ephrin-B1 expression level in 58As9 cells and 44As3 cells (Figure 1b). In addition, phosphorylation of B class ephrin was greatly reduced by knocking down ephrin-B1, as judged by the antibody recognizing phosphorylation of all three members of ephrin-Bs at the tyrosine in the cytoplasmic region (Figure 1b). From the analysis of *in vitro* Transwell assay, reducing the amount of ephrin-B1 in 44As3 cells inhibited migration and invasion through the extracellular matrix (Figure 2a). Similar results were also observed in 58As9 cells (Figure 2a). On the other

Figure 1. Tyrosine phosphorylation of ephrin-B1 is higher in invasive gastric cancer cell lines. **a:** As indicated, lysates from cells were subjected to immunoprecipitation (IP) with anti-ephrin-B1 antibody and immunoblotting (IB) with anti-phosphotyrosine antibody. The expression levels of ephrin-B1, α-tubulin, EphB2, and EphB4 in each cell lysate were confirmed by immunoblotting (bottom). When cell lysates were blotted with ephrin-B1 antibody, several ephrin-B1-reactive bands (blanket) were detected because of the glycosylation and difference in tyrosine phosphorylation as reported.³¹ **b:** Cellular levels of ephrin-B1 were analyzed 72 hours after treatment with siRNAs by Western blotting using α-tubulin as a loading control. Expression of ephrin-B1 was reduced in cells treated with ephrin-B1 siRNA (EFNB1siRNA1, 2). The phosphorylation level of ephrin-Bs was assessed by the antibody recognizing phosphorylation of Tyr317 of ephrin-B1, which also detects phosphorylation of corresponding tyrosine of ephrin-B2 (Tyr304) and ephrin-B3 (Tyr311) as described in Materials and Methods.

hand, proliferation and apoptosis of these cells were not significantly affected (Figure 2b). In addition, reduction of ephrin-B1 expression did not cause remarkable change in the adhesion of 44As3 and 58As9 cells on different extracellular matrices, including type I collagen, fibronectin, and Matrigel (Figure 2c). We further examined whether overexpression of ephrin-B1 is sufficient to promote the migration and invasion of cancer cells by stably expressing ephrin-B1 in one parental cell line HSC-58. The migration and invasion through extracellular matrix was apparently increased by the overexpression of ephrin-B1 (Figure 2d).

Phosphorylation of Ephrin-B1 Promotes Migration and Invasion of Gastric Cancer Cells

Because the level of tyrosine phosphorylation of ephrin-B1 was higher in invasive sublines of gastric cancer cells, we next examined whether blocking of ephrin-B1 phosphorylation in these cells attenuates their migration and invasion. The stable expression of ephrin-B1 with mutations of four tyrosine residues in the cytoplasmic domain (Y313, 317, 324, and 329) ephrin-B1 4YF reduced the tyrosine phosphorylation level of ephrin-B1 in 44As3 and 58As9 cells, because overexpression of eph-

rin-B1 4YF prevents endogenous ephrin-B1 from association with EphB receptors expressed in these cells (Figure 3a). From the analysis of *in vitro* Transwell assay, migration and invasion of cancer cells stably expressing ephrin-B1 4YF mutant (44As3 4YF and 58As9 4YF cells) were decreased compared with the control cells expressing mock vector (44As3 mock and 58As9 mock cells) (Figure 3b). On the other hand, expression of ephrin-B1 4YF did not affect cell proliferation under usual two-dimensional cell culture condition (Figure 3c). When these cancer cells expressing mock vector or ephrin-B1 4YF were implanted subcutaneously in nude mice, the mean size and weight of the tumors were not significantly different (Figure 3d). To understand the mechanism by which ephrin-B1 4YF attenuates the cell migration, we examined activity of Rac1 GTPase, which is a critical molecule controlling the organization of actin cytoskeleton. The activation of Rac1 was examined by affinity precipitation of GTP-bound Rac1 with the GST-fusion protein of the p21-binding domain of p21-activated kinase 1.²¹ The activated Rac1 was apparently reduced in 44As3 or 58s9 cells expressing ephrin-B1 4YF compared with the cells expressing mock vector (Figure 3e). When the appearance of cytoskeleton of these cancer cells was examined, formation of large lamellipodia was observed in most of the mock-containing 44As3 and 58As9 cells, whereas it was less frequently observed in 44As3 4YF and 58As9 4YF cells (Figure 3f), which may be consistent with the reduced Rac1 activity in cancer cells expressing ephrin-B1 4YF.

Gastric scirrhous carcinoma frequently associates with peritoneal dissemination through the process that cancer cells perforate gastric serosa and become exfoliated and free and then attached on the surface of the peritoneum and start to invade there. The effect of ephrin-B1 expression on tumor invasion was further monitored *in vitro* by overlay tumor cell invasion assay as a model system for stromal invasion of cancer cells. When 44As3 cells were plated onto the monolayer of fibroblasts, L cells, the formation of tumor cell islands was observed as tumor cells invaded and grew between the fibroblasts (Figure 4a). The formation of such tumor islands is the sign of penetration of tumor cells into the sheet of stromal cells, as used for the evaluation of cancer cell invasion through endothelial cells or mesothelial cells.^{20,22,23} The invasion of 44As3 cells into the fibroblasts monolayer was more evident when the cancer cells were plated onto L cells stably expressing EphB2 (L EphB2) than on the parent L cells, which do not express receptors for ephrin-B1⁷ (Figure 4b). The invasion foci of 44As3 in monolayer of L EphB2 cells were decreased in number and size when expression of ephrin-B1 in cancer cells was reduced (Figure 4a). In addition, the invasion of 44As3 4YF cells into the monolayer of L EphB2 cells was also decreased compared with 44As3 mock cells (Figure 4, a and b). These results indicate that activation of the signaling mediated by ephrin-B1 phosphorylation in cancer cells induced by the interaction with EphB2 receptor expressed in stromal cells enhanced the tumor invasion.

The effect of ephrin-B1 phosphorylation on tumor invasion was further examined *in vivo* using 44As3 and 58As9

Figure 2. Reduction of ephrin-B1 expression suppressed cell motility and invasion in 44As3 and 58As9 cells. **a:** 44As3 and 58As9 cells treated with ephrin-B1 siRNA (siRNA1, 2) or control siRNA or left untreated were plated onto a Transwell membrane coated with Matrigel (bottom; 85 $\mu\text{g}/\text{cm}^2$) or uncoated (top) in serum-free medium. In the lower chamber, medium containing 5% fetal bovine serum was added as a chemoattractant. After 10 hours of incubation, the wells were harvested, and cells that migrated to the lower surface of the membrane were counted. Representative fields of 44As3 cells are shown. The results from three independent experiments, each in duplicate, are shown at the right as mean $\pm$ SD. The asterisks indicate differences from the cells treated with control siRNA. $*P < 0.01$. **b:** Proliferation and apoptosis of cells were evaluated 72 hours after treatment of siRNAs. Top: Proliferation of the cells was evaluated by measurement of DNA synthesis through detection of BrdU incorporation by enzyme-linked immunosorbent assay (Roche). Bottom: Apoptosis of the cells was examined by measurement of nucleosomes through Cell death detection enzyme-linked immunosorbent assay kit (Roche). As a control, cells were treated with 50 $\mu\text{mol}/\text{L}$ etoposide for 12 hours. The results from three independent experiments, each in duplicate, are shown as the mean $\pm$ SD. **c:** Reduction of ephrin-B1 expression did not significantly affect the cell adhesion to the extracellular matrix. 44As3 and 58As9 cells treated with ephrin-B1 siRNA (siRNA1, 2) or control siRNA were detached by ethylenediamine tetraacetic acid and replated on the chamber slides coated with collagen type I (100 $\mu\text{g}/\text{ml}$), fibronectin (50 $\mu\text{g}/\text{ml}$), or Matrigel (85 $\mu\text{g}/\text{ml}$). After incubation for 30 minutes, unattached cells were removed by washing the slides in PBS (–) several times, and the remaining cells were stained with Giemsa's solution. The number of attached cells on each substrate was counted, and the results from three independent experiments, each in duplicate, are shown as the mean $\pm$ SD. **d:** Expression of wild-type ephrin-B1 promotes migration and invasion of HSC-58 cells. Wild-type ephrin-B1 was stably expressed in HSC-58 cells by retrovirus-mediated gene transfer (HSC-58 EFNB1). The cells indicated were plated onto a Transwell membrane coated with Matrigel (invasion) or uncoated (migration) in serum-free medium and assayed as described in **a**. The results from three independent experiments, each in duplicate, are shown as mean $\pm$ SD. $*P < 0.01$.

cells as a model system for peritoneal dissemination. When 58As9 or 44As3 cells expressing mock vector were injected intraperitoneally into nude mice, severe carcinomatous peritonitis was observed, as previously described (Figure 5a, top).¹⁹ Innumerable whitish nodules were observed in the mesentery of almost all mice injected with 58As9 mock cells (Figure 5a, top left) and 44As3 mock cells (data not shown). In addition, many tumor nodules of 44As3 mock cells were observed in the peritoneal cavity, including the rectouterine region with invasion into the retroperitoneum (Figure 5a, top right). On the other hand, dissemination of cancer cells expressing ephrin-B1 4YF was apparently modest. Tumor nodules of 58As9 4YF cells in the mesentery were small in size and number compared with those of control 58As9 mock cells (Figure 5b; Table 1). Such reduction of tumor nodules in the mesentery was also observed in 44As3

cells expressing ephrin-B1 4YF (Table 1). In addition, the tumor volume involving the rectouterine region was reduced in the mice injected with 44As3 4YF cells (Figure 5c). These results suggest that ephrin-B1 promotes peritoneal dissemination of 58As9 and 44As3 gastric cancer cells through signaling mediated by its tyrosine phosphorylation.

Blocking of Tyrosine Phosphorylation of Ephrin-B1 Attenuates Tumor Invasion of Orthotopic Implanted Gastric Carcinoma

To further evaluate the effect of ephrin-B1 on the process of tumor invasion, we implanted gastric cancer cells orthotopically in the gastric submucosa of nude mice. At 15 days after implantation, 70% of 44As3 tumors expressing

Figure 3. Blocking of ephrin-B1 phosphorylation suppressed cell migration *in vitro*. **a:** Lysates of cells stably expressing ephrin-B1 4YF tagged with HA at carboxyl terminus (+) or control mock vector (–) were subjected to immunoblotting with anti-HA antibody or tyrosine-phosphorylated ephrin-Bs (ephrin-B1 pY317) or immunoprecipitation of total ephrin-B1 and immunoblotting with anti-phosphotyrosine antibody (pTyr). The amount of immunoprecipitated ephrin-B1, which includes both endogenous ephrin-B1 and transfected ephrin-B1 4YF, is shown at the bottom. **b:** As indicated, the cells were seeded onto a Transwell membrane coated with Matrigel (invasion) or uncoated (migration) in serum-free medium as in Figure 2a. In the lower chamber, medium containing 5% fetal bovine serum was added. After 10 hours of incubation, the wells were harvested, and cells that migrated to the lower surface of the membrane were counted. Representative fields are shown. The results from three independent experiments, each in duplicate, are shown at the bottom as mean $\pm$ SD. * $P < 0.01$. **c:** Proliferation of the cells under the culture in the medium containing 10% serum was evaluated by counting the cell number at different time points after being plated onto dishes. **d:** 44As3 and 58As9 cells (1×10^7 cells/mice) expressing either mock or ephrin-B1 4YF were implanted subcutaneously in the flank of nude mice, and the mice were sacrificed 5 weeks after implantation. The mean weight $\pm$ SD of eight subcutaneous tumors is shown at the bottom. **e:** Activation of Rac1 was examined by affinity precipitation of GTP-bound Rac1 (Rac1-GTP) with GST-PBD as described in Materials and Methods. The precipitated Rac1-GTP and total Rac1 in each cell lysate were detected by immunoblotting with anti-Rac1 antibody. **f:** Morphology of gastric cancer cells was monitored. The cells were fixed around 12 hours after plating and stained with phalloidin as described in Materials and Methods for detection of F-actin.

the mock vector formed a large tumor mass involving the greater omentum because of the disruption of gastric serosa and invasion into the surrounding fat tissue (Figure 6a). On the other hand, such local invasion into the omentum was less frequently observed (18%) in mice implanted with 44As3 4YF cells, and most tumors remained within the gastric wall at day 15 (Figure 6a; Table 2). The dissemination of 44As3 mock cells was also observed in several tissues, including the liver surface and mesenteric sheets (Figure 6, b and c). However, we rarely observed cancer dissemination in the peritoneal cavity in mice implanted with 44As3 4YF cells (Figure 6, b and c; Table 2).

Histological examination revealed that expression of ephrin-B1 4YF did not greatly change the morphology of the tumor in the gastric wall (Figure 7, c, d, l, and m). However, invasion of control 44As3 mock cells into lymphatic vessels in subserosa and metastasis to the regional lymph nodes was more frequently observed than 44As3 4YF cells at day 10 after tumor implantation (70 and 18%, respectively; Figure 7, e–g; Table 3). Histolog-

ical analysis also revealed that the tumor had already reached the outside of the serosal surface and invaded into the surrounding fat tissue in 80% of mice implanted with 44As3 mock cells, whereas it was of low frequency in mice implanted with 44As3 4YF cells (27%) (Figure 7, h and i; Table 3). These phenotypes, including lymphatic vessel invasion, lymph node metastasis, and perforation of gastric serosa, were developed in the same mice, and all three phenotypes are overlapped in 7 of 10 mice in the mock group and in 2 of 10 mice in the 4YF group, suggesting that these are sequential or correlated events. These results indicate that the disruption of signaling mediated by phosphorylation of ephrin-B1 suppressed the invasion and peritoneal dissemination of scirrhous gastric carcinomas.

Discussion

Ephrin-B1 plays pivotal roles in the migration and invasion of cancer cells. High invasion potential is one of the

a overlay tumor invasion assay

Figure 4. Invasion of ephrin-B1-expressing cells was promoted by interaction with EphB2 receptor. **a:** 44As3 cells were highly invasive into the monolayer of fibroblasts expressing EphB2, which was attenuated by reduction of ephrin-B1 expression. When L cells or L EphB2 cells grew to confluent state in 24-well plates, DiO-labeled 44As3 cells treated either with control or ephrin-B1 siRNA or with 44As3 mock or 44As3 4YF cells (1×10^4 , each) were seeded onto the monolayer and incubated in a medium containing 10% fetal bovine serum for 15 hours. Representative fields of the co-culture are shown (top, $\times 100$; bottom, $\times 200$). **Arrowheads** indicate typical invasion foci of tumor cells. Bottom: Typical invasion focus of tumor cells is shown in the fluorescence field ($\times 200$). The nest of invaded tumor cells is surrounded by **arrowheads**. **b:** The number of invasion foci was counted as described in Materials and Methods, and the results from three independent experiments, each in duplicate, are shown as mean $\pm$ SD. The **asterisks** indicate differences from the cells treated with control siRNA or control cells expressing mock vector. $*P < 0.01$. The **arrows** indicate unfocused Dio-labeled tumor cells, which did not invade but grew on the monolayer.

major characteristics of scirrhous carcinoma, which determines the poor prognosis of this type of cancer. Using two scirrhous gastric cancer cell lines with high invasion potential, we show for the first time that ephrin-B1 modifies cancer invasion *in vivo*. Blocking of the signaling mediated by tyrosine phosphorylation of ephrin-B1 suppressed the invasion and peritoneal dissemination of these scirrhous cancer cells. Notably, attenuation of phosphorylation of ephrin-B1 suppressed orthotopically implanted scirrhous cancer cells invading through the gastric wall and into the lymphatic vessels. The significance of ephrin-B1 in the invasive phenotype of cancer cells was further obtained from the result that stable expression of wild-type ephrin-B1 in HSC-58, the parental cell line of 58As9 cells, actually promoted the migration and invasion of this cell line *in vitro* (Figure 2d).

Association with EphB receptors triggers tyrosine phosphorylation of ephrin-B1, including Tyr317 (corresponding to Tyr298 of *Xenopus* ephrin-B1), by Src family kinases, which is a critical requirement for interaction with an Src homology 2/Src homology 3 adaptor, Grb4, to

transduce signaling.¹⁶ In the physiological conditions, phosphorylation of ephrin-B1 is induced by the contact of ephrin-B1-expressing cells with heterologous cells expressing EphB receptors. On the other hand, ephrin-B1 also promotes migration of cancer cells in a cell-autonomous mechanism as observed in Transwell assay (Figures 2 and 4b). Because EphB2 receptor was expressed in 44As3 and 58As9 cells and expression of EphB4 was also detected in 44As3 cells (Figure 1a), there is a possibility that ephrin-B1 in these cancer cells may be constitutively stimulated by EphB receptors coexpressed in the same cell surface or contacting neighboring cancer cells. This conclusion may be consistent with the observation that the basal phosphorylation level of ephrin-B1 is elevated in 44As3 and 58As9 cells under the usual two-dimensional culture condition *in vitro* (Figure 1a). Overexpression of ephrin-B1 4YF may suppress tumor invasion *in vivo* by blocking cell autonomous phosphorylation of ephrin-B1 in cancer cells and the induction of ephrin-B1 phosphorylation through the interaction with stromal cells. There is still the possibility that expression of eph-

Figure 5. Disruption of ephrin-B1 phosphorylation suppressed the peritoneal dissemination of 44As3 and 58As9 cells. Cells stably expressing a mock vector or ephrin-B1 4YF were injected intraperitoneally into nude mice (5×10^6 cells/mice). **a:** Representative appearance of peritoneal dissemination two weeks after injection is shown. Left: **Asterisk** indicates dissemination of cancer nodules in the mesentery, and **arrows** indicate the tumor mass, including greater omentum. Right: The pictures were taken after resection of intestinal loops. **Arrowheads** indicate the tumor nodules of 44As3 cells disseminated around the rectouterine region and retroperitoneum. **b:** Representative dissected intestinal loops from four or five mice injected with 58As9 mock or 58As9 4YF cells, respectively. Note large tumor nodules in the mesentery of mice injected with control mock cells. **c:** Representative appearance of the tumors of 44As3 cells involving rectouterine region was compared. **Yellow** and **red arrowheads** indicate uterine horns and tumor mass, respectively.

rin-B1 4YF may also block the signaling mediated by other members of ephrin-Bs that also bind the similar group of EphB receptors. However, knocking down of ephrin-B1 by siRNA greatly reduced the phosphorylation of total ephrin-Bs (Figure 1b), suggesting that ephrin-B1, but not ephrin-B2 or ephrin-B3, is the major member of B-class ephrin, which is phosphorylated in these cells. Consistent with this conclusion, at least treatment of 44As3 and 58As9 cells with ephrin-B2 siRNA did not affect the phosphorylation level of the corresponding tyrosine residue of ephrin-Bs examined by anti-ephrin-B1 pY317 antibody (data not shown).

The ephrin/Eph interaction provides both ephrin-B1-mediated reverse signaling and EphB-mediated forward signaling. The expression of ephrin-B1 4YF may suppress the invasion of gastric cancer cells by stimulation of EphB receptor-mediated forward signaling in cancer cells through acting as a stimulator of EphB receptors,

because EphB receptor-mediated forward signaling inhibited migration of colorectal tumors in a recent report.²⁴ However, cancer cell invasion was also inhibited by treatment with ephrin-B1 siRNA, which should cause reduction of forward signaling. Therefore, such inhibitory effect of forward signaling caused by the overexpression of the ligand, even if it exists, does not seem to be strong. In addition, we previously observed that overexpression of ephrin-B1 in Panc1 and Capan1 pancreas cancer cells, in which EphB2 is endogenously expressed, promoted the peritoneal dissemination of these cells by the similar experiment in this study (data not shown), which may also support this conclusion.

We observed that ephrin-B1-expressing cancer cells invaded more frequently into the monolayer of fibroblasts expressing EphB2 receptor than into the parent fibroblasts in overlay invasion assay. This result suggests that cancer cells expressing ephrin-B1 may actively invade into the stromal tissues that express EphB receptors, and such mechanism may also be involved in the process of peritoneal dissemination of ephrin-B1-expressing cancer cells *in vivo*. For example, stromal cells composed of mouse mesentery sheets actually expressed cognate receptors for ephrin-B1 (Supplemental Figure 1 at <http://ajp.amjpathol.org>). Again, there is a possibility that EphB2-mediated forward signaling in L EphB2 fibroblasts also contributes to the formation of invasion foci of cancer cells in this overlay assay. However, expression of ephrin-B1 4YF prevented the invasion of 44As3 cells into the monolayer of L EphB2 cells, suggesting that this invasion

Table 1. Mesenterial Dissemination after Intraperitoneal Inoculation of Gastric Cancer Cells

Cell	Number of nodules*		
	0 to 10	10 to 30	>30
44As3 mock	0	5	15
44As3 4YF	14	5	1
58As9 mock	0	2	18
58As9 4YF	16	3	1

Mice were sacrificed at 14 days after inoculation. Data are shown as the number of mice bearing tumors in the mesentery.

*Number of tumor nodules larger than 2 mm in the mesentery.

44As3 orthotopic implantation

Figure 6. Disruption of ephrin-B1 phosphorylation suppressed the peritoneal dissemination of orthotopically implanted 44As3 cells. 44As3 cells expressing either mock or ephrin-B1 4YF were orthotopically implanted in submucosa of the gastric wall as described in Materials and Methods. The representative macroscopic views of dissected organs 15 days after implantation, including stomach with spleen (**a**), liver (**b**), and intestine (**c**), are shown. **Arrowheads** indicate the area involving the tumor (**a**). The right panels of **c** show high magnification of the mesentery in the middle panels. **Yellow arrowheads** indicate white tumor nodules.

is considered to depend predominantly on the ephrin-B1-mediated reverse signaling in cancer cells rather than the forward signaling in fibroblasts.

Tumor cells expressing ephrin-B1 may gain invasiveness in multiple steps of the cell invasion process. Phosphorylation of ephrin-B1 leads to the recruitment of scaffolding protein disheveled via Grb4, which results in aberrant activation of RhoA.^{25,26} Ephrin-B1 makes a complex with Tiam1 to induce Rac1 activation,²⁰ and we showed blocking of tyrosine phosphorylation of ephrin-B1 decreased the Rac1 activity in this study. Ephrin-B1 is also phosphorylated on tyrosine residues through physical association with cell adhesion proteins such as claudin, which attenuates the cell-cell adhesion.⁷ In addition, EphB2-induced phosphorylation of ephrin-B1 has been reported to modify the cell-to-substrate adhesion,¹⁷ although reduction of ephrin-B1 with siRNA did not significantly affect cell adhesion to several substrates

in vitro under the condition that ephrin-B1 was not stimulated with exogenous EphB2 receptor. Therefore, phosphorylation of ephrin-B1 may regulate cell motility also by affecting the cell adhesion to substrates in the process of stromal invasion of tumors *in vivo*. Blocking of ephrin-B1 phosphorylation by the ephrin-B1 4YF mutant may inhibit tumor invasion through blocking such multiple events.

We cannot exclude a possibility that phosphorylation-independent signaling of ephrin-B1 is also involved in the regulation of cancer cell invasion. For example, proteins containing PDZ domains make a stable complex with ephrin-B1 via PDZ domain-binding motif -YXV located at the carboxyl terminus of ephrin-B1.²⁷ It may be important to examine the phosphorylation state of ephrin-B1 *in vivo* in a wide range of cancers to estimate what types of cancers will be sensitive for blocking ephrin-B1 phosphorylation on tumor suppression. For example, phosphorylation of B-type ephrins in invading glioblastoma has been reported recently.¹⁴

We performed intraperitoneal inoculation of cancer cells into nude mice as a model of peritoneal dissemination of the tumor, as also reported by others.^{28,29} Although many gastric cancer cell lines do not show typical histological appearance of human scirrhous carcinoma when inoculated into nude mice, our system of orthotopic transplantation of 44As3 cells is a highly reproducible animal model of peritoneal dissemination of human scir-

Table 2. Dissemination at 15 Days after Orthotopic Implantation of 44As3 Gastric Cancer Cells

Cell	Omentum	Liver	Mesentery
Mock	7/10 (70)	5/10 (50)	7/10 (70)
4YF	2/11 (18)	1/11 (9)	2/11 (18)

Number of mice bearing tumor at the site per total number of mice bearing tumor (%).

Figure 7. Histology of stomach 10 days after orthotopic implantation of 44As3 cells expressing either mock (**a–i**) or ephrin-B1 4YF (**j–m**) H&E stain. **a, b, j, and k:** Red arrowheads indicate the area occupied by tumor ($\times 20$). High magnification of the center of the tumor (blue box) is shown in **c, d, l, and m**, respectively ($\times 100$). Metastasis to the regional lymph nodes (boxed area in **a** and **b**, indicated by an asterisk) is shown in **e** and **f** with high magnification ($\times 200$). Note that there are numerous cancer cells containing signet-ring cells. Infiltration of cancer cells into lymphatic vessels at the peripheral region of the tumor (boxed area in **a**, indicated by #) is shown in **g** as an enlarged view. **h** and **i:** Invasion of cancer cells into fat tissue surrounding the stomach. The boxed area in **h** is enlarged in **i**. M, mucosa; MP, muscularis propria; SS, subserosa. Arrows indicate esophageal mucosa (**b** and **k**).

rhous gastric carcinoma.^{18,19,30} Because early clinical diagnosis of scirrhous gastric carcinoma is difficult, peritoneal dissemination or metastasis to lymph nodes has frequently occurred by the time the diagnosis is made. We observed that expression of ephrin-B1 4YF suppressed not only local invasion of 44As3 cells in the gastric wall but also the infiltration of cancer cells into lymphatic vessels and lymph node metastasis. These results suggest that ephrin-B1 phosphorylation-mediated signaling may modulate the process of the invasion of cancer cells to lymphatic vessels. It may be useful to examine the expression and phosphorylation level of ephrin-B1 in a surgical specimen of scirrhous gastric carcinomas to predict lymphatic metastasis of tumors. Dissemination is a frequent form of the recurrence of scirrhous gastric carcinoma, which serves as a major factor determining the prognosis. Ephrin-B1 is consid-

ered to be a prognostic factor of gastric scirrhous carcinoma, and the inhibition of a specific cellular signal originating in ephrin-B1 phosphorylation may be a good candidate for regulating its invasion and dissemination.

References

- Blits-Huizinga C, Nellersa C, Malhotra A, Liebl D: Ephrins and their receptors: binding versus biology. *IUBMB Life* 2004, 56:257–265
- Murai, KK, Pasquale EB: Ephective signaling: forward, reverse and crosstalk. *J Cell Sci* 2003, 116:2823–2832
- Poliakov A, Cotrina M, Wilkinson DG: Diverse roles of Eph receptors and ephrins in the regulation of cell migration and tissue assembly. *Dev Cell* 2004, 7:465–480
- Battle E, Henderson JT, Beghtel H, Van den Born M, Sancho E, Huls G, Meeldijk J, Robertson J, Van de Wetering M, Pawson T, Clevers H: β -Catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. *Cell* 2002, 111:251–263
- Battle E, Bacani J, Beghtel H, Jonkheer S, Gregorieff A, Van den Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H: EphB receptor activity suppresses colorectal cancer progression. *Nature* 2005, 435:1126–1130
- Holmberg J, Genander M, Halford MM, Anneren C, Sondell M, Chumley MJ, Silvary RE, Henkemeyer M, Frisen J: ephB receptors coordinate migration and proliferation in the intestinal stem cell niche. *Cell* 2006, 125:1151–1263
- Tanaka M, Kamata R, Sakai R: Phosphorylation of ephrin-B1 via the interaction with claudin following cell-cell contact formation. *EMBO J* 2005, 24:3700–3711
- Tanaka M, Kamata R, Sakai R: EphA2 phosphorylates the cytoplas-

Table 3. Histological Analysis of the Stomach 10 Days after Orthotopic Implantation of 44As3 Cells

Cell	ly ves	Lymph node	Perforation
Mock	7/10 (70)	7/10 (70)	8/10 (80)
4YF	2/11 (18)	2/11 (18)	3/11 (27)

Data are shown as the number of mice bearing tumor with lymphatic vessel invasion (ly ves), metastasis to regional lymph nodes (lymph node), or perforation of the gastric serosa and infiltrating to the surrounding fat tissue (perforation) per total number of mice bearing tumor (%).

- mic tail of claudin-4 and mediates paracellular permeability. *J Biol Chem* 2005, 280:42375–42382
9. Surawska H, Ma PC, Salgia R: The role of ephrins and Eph receptors in cancer. *Cytokine Growth Factor Rev* 2004, 15:419–433
10. Sawai Y, Tamura S, Fukui K, Ito N, Imanaka K, Saeki A, Sakuda S, Kiso S, Matsuzawa Y: expression of ephrin-B1 in hepatocellular carcinoma: possible involvement in neovascularization. *J Hepatol* 2003, 39:991–996
11. Meyer S, Hafner C, Guba M, Flegel S, Geissler EK, Becker B, Koehl G, Orso E, Landthaler M, Vogt T: Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. *Int J Oncol* 2005, 27:1197–1206
12. Castellvi J, Garcia A, De la Torre J, Hernandez J, Gil A, Xercavins J, Cajal SR: EphrinB expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis. *Hum Pathol* 2006, 37:883–889
13. Varelias A, Koblar SA, Cowled PA, Carter CD, Clayer M: Human osteosarcoma express specific ephrin profiles: implications for tumorigenicity and prognosis. *Cancer* 2002, 95:862–869
14. Nakada M, Drake KL, Nakada S, Niska JA, Berens ME: Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. *Cancer Res* 2006, 66:8492–8500
15. Kataoka H, Tanaka M, Kanamori M, Yoshii S, Ihara M, Wang YJ, Song JP, Li ZY, Arai H, Otuki Y, Kobatashi T, Kohno H, Hanai H, Sugimura H: Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. *J Cancer Res Clin Oncol* 2002, 128:343–348
16. Bong YS, Park YH, Lee HS, Mood K, Ishimura A, Daar IO: Tyr-298 in ephrin-B1 is critical for an interaction with the Grb4 adaptor protein. *Biochem J* 2004, 377:499–507
17. Cowan CA, Henkemeyer M: The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. *Nature* 2001, 413:174–179
18. Yanagihara K, Tanaka H, Takigahira M, Ino Y, Yamaguchi Y, Toge T, Sugano K, Hirohashi S: Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. *Cancer Sci* 2004, 95:575–582
19. Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, Nishio K, Ochiya T, Ino Y, Hirohashi S: Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. *Cancer Sci* 2005, 96:323–332
20. Akedo H, Shinkai K, Mukai M, Mori Y, Tateishi R, Tanaka K, Yamamoto R, Morishita T: Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: a model for tumor invasion. *Cancer Res* 1986, 46:2416–2422
21. Tanaka M, Ohashi R, Nakamura R, Shinmura K, Kamo T, Sakai R, Sugimura H: Tiam1 mediates neurite outgrowth induced by ephrin-B1 and EphA2. *EMBO J* 2004, 23:1075–1088
22. Kusama T, Mukai N, Tatsuta M, Nakamura H, Inoue M: Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. *Int J Oncol* 2006, 29:217–223
23. Blaheta RA, Daher FH, Michaelis M, Hasenberg C, Weich EM, Jonas D, Kotchetkov R, Doerr HW, Cinatl Jr J: Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. *BMC Cancer* 2006, 6:294
24. Guo DL, Zhang J, Yuen ST, Tsui WY, Chan ASY, Ho C, Ji J, Leung SY, Chen X: Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumors. *Carcinogenesis* 2006, 27:454–464
25. Tanaka M, Kamo T, Ota S, Sugimura H: Association of dishevelled with Eph tyrosine kinase receptor and ephrin mediates cell repulsion. *EMBO J* 2003, 22:847–858
26. Lee HS, Bong YS, Moore KB, Soria K, Moody SA, Daar IO: Dishevelled mediates ephrinB1 signalling in the eye field through the planar cell polarity pathway. *Nat Cell Biol* 2006, 8:55–63
27. Lin D, Gish GD, Songyang Z, Powson T: The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif. *J Biol Chem* 1999, 274:3726–3733
28. Li Z, Zhan W, Wang Z, Zhu B, He Y, Peng J, Cai S, Ma J: Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via micro RNA suppressed peritoneal metastasis. *Biochem Biophys Res Commun* 2006, 348:229–237
29. Arlt MJE, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, Honer M, Schubiger A, Altevogt P, Kruger A: Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. *Cancer Res* 2006, 66:936–943
30. Yanagihara K, Takigahira M, Takeshita F, Komatsu T, Nishio K, Hasegawa F, Ochiya T: A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. *Cancer Res* 2006, 66:7532–7539
31. Holland SJ, Gale NW, Mbamalu G, Yancopoulos GD, Henkemeyer M, Powson T: Bidirectional signaling through the EPH-family receptor Nuk and its transmembrane ligands. *Nature* 1996, 383:722–725